ROCKVILLE, Md., Feb. 23, 2010 (GLOBE NEWSWIRE) -- Cytomedix, Inc. (NYSE Amex:GTF), a leading developer of biologically active regenerative therapies for wound care, inflammation and angiogenesis, today announced that the Company's lead product, the AutoloGel™ System, is highlighted in the current issue of "Hair Transplant Forum International," the bi-monthly publication of the International Society of Hair Restoration Surgery. The article is authored by internationally renowned hair restoration specialist, Robert J. Reese, D.O., and is titled, "Autologous Platelet Rich Plasma (PRP): What Do We Know? Important Concepts Relevant To Hair Restoration Surgery."
According to the article, "Relating to hair restoration, the application of PRP has been evaluated as a treatment to both speed wound healing and foster hair growth. Both of these endpoints relate to the delivery of growth factor, cytokine, and chemokine activities, and based upon available past and present data, this author suggests that PRP containing physiologic concentrations of platelets is most appropriate."
In his review, Dr. Reese discusses several factors that affect his choice of Cytomedix's AutoloGel System as the optimal PRP therapy for wounds associated with hair restoration surgery including:
- The AutoloGel System is the only PRP system that is FDA cleared for the care of wounds.
- The AutoloGel System produces an end product derived from physiologic concentrations of platelets that is activated with thrombin to produce active PRP gel.
- The AutoloGel System produces a PRP that has no or minimal contaminating red cells or leukocytes. The presence of which is an obvious aesthetic consideration and recent data supports that contaminating leukocytes may detrimentally impact performance.
The author recommends that, "for purposes of safety, efficacy, and standardization across the hair restoration community, investigators consider the Cytomedix AutoloGel System, which produces activated PRP gel from physiological concentrations of platelets with little or no contaminating red cells or leukocytes."
"Dr. Reese's article makes a strong clinical case for the inclusion of the AutoloGel System in hair transplantation surgery. We concur with his findings and believe this represents an attractive market opportunity for the AutoloGel System," noted Martin Rosendale, Chief Executive Officer of Cytomedix.
The full article is available at http://www.cytomedix.com/docs/reese_article_prp.pdf">http://www.cytomedix.com/docs/reese_article_prp.pdf
About Cytomedix
Cytomedix develops, sells and licenses regenerative biological therapies including the AutoloGel™ System, a device for the production of Platelet Rich Plasma ("PRP") gel derived from the patient's own blood. The AutoloGel™ System is cleared by the U.S. Food and Drug Administration for use on a variety of exuding wounds. The Company is pursuing a multi-faceted strategy to penetrate the chronic wound market with its AutoloGel™ System. The Company is also moving forward with the development of other product candidates in its pipeline. Most notably is its CT-112 product, an anti-inflammatory peptide that has shown promise in preclinical testing. Additional information regarding Cytomedix is available at www.cytomedix.com.
About Hair Transplant Forum International
Hair Transplant Forum International is a privately published newsletter of the International Society of Hair Restoration Surgery. Its contents are solely the opinions of the authors and are not formally "peer reviewed" before publication. To facilitate the free exchange of information, a less stringent standard is employed to evaluate the scientific accuracy of the letters and articles published in the Forum. The standard of proof required for letters and articles is not to be compared with that of formal medical journals. The newsletter was designed to be and continues to be a printed forum where specialists and beginners in hair restoration techniques can exchange thoughts, experiences, opinions, and pilot studies on all matters relating to hair restoration.
Safe Harbor Statement
Statements contained in this communication not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Cytomedix's actual results may differ materially due to a number of factors, many of which are beyond Cytomedix's ability to predict or control, including among others, viability and effectiveness of the Company's sales approach and overall marketing strategies, the outcome of development or regulatory review of CT-112, commercial success or acceptance by the medical community, competitive responses, the Company's ability to raise additional capital and to continue as a going concern, its ability to successfully commercialize its product in Japan under the terms of the license agreement, and Cytomedix's ability to execute on its strategy to market the AutoloGel™ System as contemplated. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. More information about some of these risks and uncertainties may be found in the reports filed with the Securities and Exchange Commission by Cytomedix, Inc. Cytomedix operates in a highly competitive and rapidly changing business and regulatory environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Except as is expressly required by the federal securities laws, Cytomedix undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.